招待講演3[Clinical Trial Network Session] 11月4日

Total Page:16

File Type:pdf, Size:1020Kb

招待講演3[Clinical Trial Network Session] 11月4日 第56回日本核医学会学術総会 招待講演 招待講演1[SNMMI Session] 11月4日㈮8:30~9:30 第2会場 座長:藤林 靖久(量子科学技術研究開発機構 放射線医学総合研究所) US GMP PET Drug Production (Washington University School of Medicine, Department of Radiology, USA)Sally W. Schwarz 特別企画プログラム 招待講演2[EANMI Session] 11月4日㈮9:30~10:30 第2会場 座長:小泉 潔(東京医科大学八王子医療センター 放射線科) Molecular imaging and therapy of prostate cancer (European Association of Nuclear Medicine(EANM), Austria)Bernd Krause 招待講演3[Clinical Trial Network Session] 11月4日㈮10:30~11:30 第2会場 座長:千田 道雄(先端医療センター分子イメージング研究グループ) Synthesis and Imaging of Neuroendocrine Tumors Using Ga-68 Labeled Somatostatin Analogs (Radiochemistry, Department of Radiology, University of Iowa, USA)David W. Dick 招待講演4 11月4日㈮13:10~14:10 第2会場 座長:岡沢 秀彦(福井大学高エネルギー医学研究センター) Positron Emission Tomography of Human Brain can Monitor Neuroinammation and cAMP Signaling: Applications to Alzheimer's Disease and Depression (Molecular Imaging Branch, NIH(National Institute of Health), USA)Robert B. Innis 招待講演5 11月4日㈮14:10~15:00 第2会場 座長:樋口 隆弘( ヴュルツブルク大学・ドイツ総合心不全センター 心臓分子イメージ ング研究部門) Molecular Imaging and Therapy in Prostate Cancer: from Choline to PSMA and beyond (Universitätsklinikum Ulm/Klinik für Nuklearmedizin, Germany)Ambros J. Beer 招待講演6 11月4日㈮9:40~10:30 第7会場 座長:中駄 邦博(北光記念病院放射線科) Diagnostic 131-I scintigraphy with SPECT/CT for the management of thyroid cancer (Department of Radiology University of Michigan Medical Center, USA)Anca M. Avram ―S75― 第56回日本核医学会学術総会 招待講演7 11月4日㈮9:30~10:15 第10会場 座長:小田野行男( 仙台画像検診クリニック/ カロリンスカ大学精神神経科研究アドバイザー) Molecular imaging of the dopamine transporter in Parkinson's disease (Karolinska Institutet, Department of Clinical Neuroscience, Centre for Psychiatry Research, 特別企画プログラム Karolinska University Hospital, Sweden)Andrea Varrone シンポジウム シンポジウム1[心臓・循環器] 11月3日㈭9:00~12:00 第1会場 Imaging of Atherosclerotic Plaque: Current Progress and Future Prospects Moderator:Jagat Narula(Icahn School of Medicine at Mount Sinai, USA) Nagara Tamaki( Hokkaido University) 1.Imaging for the Management of Stable IHD: Anatomy, Physiology or Morphology? (Icahn School of Medicine at Mount Sinai, USA)Jagat Narula 2.Atherosclerotic plaque imaging with various PET tracers ~ Animal studies ~ (Graduate School of Pharmaceutical Sciences, Hokkaido University)Mikako Ogawa 3.Coronary CT angiography for plaque assessment (Department of Cardiology, Fujita Health University)Sadako Motoyama 4.Clinical monitoring of inammatory activity in atherosclerotic disease (Department of Medicine, Division of Cardiovascular Medicine, Kurume University School of Medicine) Nobuhiro Tahara 5.Clinical evidences of CMR in atherosclerotic plaques (Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center)Teruo Noguchi シンポジウム2[機器] 11月4日㈮8:30~11:30 第3会場 SPECTの新たな世界をめざして 座長:中原 理紀(慶応義塾大学放射線診断科) 佐々木雅之(九州大学大学院医用量子線科学) 1.SPECT/CTによるSUV値を用いた腎静態DMSAシンチの3D計測について (国立成育医療研究センター 放射線診療部 放射線治療科)北村 正幸 2.定量的SPECT/CTによる新たな核医学の可能性 (埼玉医大国際医療センター 核医学科)久慈 一英 3.Quantitative 99mTc-Sestamibi SPECT/CT in patients with hyperparathyroidism (大阪大学大学院医学系研究科 医薬分子イメージング学寄附講座)松永 恵子 4.SPECTの定量的評価とその臨床活用への試み (三重大学医学部附属病院 放射線診断科)市川 泰崇 5.腫瘍核医学におけるSPECT検査の有用性-定量評価とRI治療への応用- (金沢大学核医学診療科)稲木 杏吏 ―S76― 第56回日本核医学会学術総会 6.123I標識脳血流SPECTの標準化と共通正常データベースの構築 (藤田保健衛生大学 医学部 放射線医学)乾 好貴 シンポジウム3[分子イメージング] 11月4日㈮8:30~11:30 第1会場 Multi-modality imaging -From basic principles to clinical applications- Moderator:Mikako Ogawa(Hokkaido University) 特別企画プログラム Hirofumi Fujii( National Cancer Center) 1.Molecular Imaging of the Immune System (Stanford University, USA)Sanjiv Sam Gambhir 2.Library-based approach to realize intraoperative rapid uorescent imaging of tiny tumors (Graduate School of Pharmaceutical Sciences and Graduate School of Medicine, The University of Tokyo) Yasuteru Urano 3.PET molecular imaging for clinical application (Department of Nuclear Medicine, Osaka University Graduate School of Medicine)Tadashi Watabe 4.Faster than the speed of light - Cerenkov Imaging and its application (Memorial Sloan Kettering Cancer Center, New York, NY, USA)Jan Grimm 5.Quantitative brain analysis of small animals using PET and histopathological analysis (Department of Radiology, Fujita Health University)Hiroshi Toyama シンポジウム4[薬剤] 11月4日㈮13:10~15:10 第3会場 次世代の核医学イメージング剤 座長:間賀田泰寛(浜松医科大学 光尖端医学教育研究研究センター) 西井 龍一(量子科学技術研究開発機構 放射線医学総合研究所) 1.多価 99mTc 錯体を用いる脳アミロイドアンギオパチーの核医学イメージング (京都大学 薬学研究科)小野 正博 2.フッ素18標識心筋イメージング剤の開発 (東北大学サイクロトロン・ラジオアイソトープセンター 核薬学研究部)古本 祥三 3.前立腺特異的膜抗原(PSMA)を標的としたイメージングプローブの開発研究 (京都薬科大学 代謝分析学分野)木村 寛之 4.臨床応用を目指したPET薬剤の次世代化 (東京都健康長寿医療センター研究所 神経画像研究チーム)豊原 潤 5.希少核種の容易な製造に関する試み (量子科学技術研究開発機構 放射線医学総合研究所 標識薬剤開発部)永津弘太郎 ―S77― 第56回日本核医学会学術総会 シンポジウム5(スポンサードシンポジウム)[アルファ線内用療法] 11月5日㈯9:00~11:30 第1会場 骨転移治療の新しい選択肢のRa-223:診療科横断的な取り組み 座長:畑澤 順(大阪大学放射線統合医学講座) 井上登美夫(横浜市立大学放射線科) 1.Clinical application of Ra-223: the new treatment option for CRPC with bone-metastases 特別企画プログラム (Institute of Cancer Research / Royal Marsden Hospital, UK)Win J. G. Oyen 2.国内におけるRa-223の臨床上の使われ方:診療科による役割分担について―核医学医の立場 (金沢大学医薬保健研究域医学系 核医学)絹谷 清剛 3.骨転移治療(Ra-223)導入に向けた取り組み (横浜市立大学附属病院放射線部)尾川 松義 4.「骨転移治療の新しい選択肢のRa-223:診療科横断的な取り組み」-泌尿器科の立場から- (日本医科大学泌尿器科学)木村 剛 共催:バイエル薬品株式会社 シンポジウム6[Amyloid and tau PET] 11月5日㈯9:00~11:10 第2会場 The cutting edge of demenita research using amyloid and tau PET Moderator:Kenji Ishii(Tokyo Metropolitan Geriatric Hospital) Hitoshi Shimada( National Institutes for Quantum and Radio- logical Science and Technology) 1.Aβ-amyloid and tau imaging in dementia (University of Melbourne, AUS)Victor L. Villemagne 2.Impact of tau PET on dementia research (Department of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University) Nobuyuki Okamura 3.Development of novel PET/SPECT imaging probes targeting amyloid and tau (Graduate School of Pharmaceutical Sciences)Masahiro Ono 4.Novel plasma biomarker surrogating cerebral amyloid deposition in Alzheimerʼs disease (Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation)Naoki Kaneko 5.Electrophysiological biomarkers for Alzheimerʼs Disease (Department of Clinical and Experimental Neuroimaging, National Center for Geriatrics and Gerontology) Akinori Nakamura シンポジウム7[PETによる腫瘍診断] 11月3日㈭14:30~17:30 第11会場 オンコロジーPETイメージング:様々な放射性医薬品の現状と可能性 座長:長町 茂樹(宮崎大学医学部附属病院放射線部) 立石宇貴秀(東京医科歯科大学大学院医歯学総合研究科画像診断・核医学分野) 1.68Gaオクトレオタイドを用いたソマトスタチン受容体イメージング (京都大学大学院 医学研究科 放射線医学講座(画像診断学・核医学))中本 裕士 ―S78― 第56回日本核医学会学術総会 2.腹部領域における 18F-FLT PET/CTの有用性について (鹿児島大学医歯学総合研究科 放射線診断治療学)中條 正豊 3.DNA合成イメージング剤 11C-4DSTの臨床使用経験 (香川大学医学部 放射線医学講座)山本 由佳 4.Na/F PETの現状 (メディポリス東京クリニック)山口慶一郎 特別企画プログラム 5.臨床におけるメチオニンPETの有用性 (国立国際医療研究センター放射線核医学)南本 亮吾 6.低酸素PETによる難治がん診断 (京都大学医学部附属病院 放射線診断科)佐賀 恒夫 核医学教育講演 核医学教育講演1 11月3日㈭9:00~10:00 第2会場 乳房PET:見えた!見つけた!の時代は終わった。これからは次のステージだ! 座長:細野 眞(近畿大学高度先端総合医療センター) 川本 雅美(ゆうあいクリニック) 1.乳房 PETエルマンモ:「全身PETで確認できません」から「見えすぎて困る!」時代へ: 病理像との対比を含め (木沢記念病院)西堀 弘記 2.対向型PEMの利用法 (仙台画像検診クリニック)伊藤 正敏 3.PEMを臨床現場で使いこなす (医療法人DIC 宇都宮セントラルクリニック)佐藤 俊彦 核医学教育講演2 11月3日㈭10:00~11:00 第2会場 ミスフォールディング蛋白質の画像化と次世代神経疾患イメージング 座長:百瀬 敏光( 東京大学大学院医学系研究科生体物理医学専攻 放射線医学講座 核医学分野) 石井 一成(近畿大学医学部 放射線医学教室) 1.ミスフォールディング蛋白画像化プローブの開発 (東北大学加齢医学研究所)工藤 幸司 2.アミロイドイメージング・タウイメージングの画像・評価法 (放射線医学総合研究所 脳機能イメージング研究部)市瀬 正則 3.アミロイド/タウPETの臨床応用 (東京都健康長寿医療センター研究所神経画像研究チーム)石井 賢二 ―S79― 第56回日本核医学会学術総会 核医学教育講演3 11月3日㈭11:00~12:00 第2会場 脳SPECTによる脳機能評価のupdate 座長:桑原 康雄(福岡大学病院放射線部第二) 中川原譲二(国立循環器病研究センター循環器病統合イメージングセンター) 1.脳虚血後の組織障害:新規SPECT製剤によるバイオマーカーの評価 特別企画プログラム (大阪大学大学院 医学系研究科)下瀬川恵久 2.頭部外傷患者における核医学検査の意義と課題 (北海道大学大学院医学研究科病態情報学講座 核医学分野)志賀 哲 3.イオフルパンSPECTの正常データベース構築 (国立精神・神経医療研究センターIBICセンター)松田 博史 核医学教育講演4 11月3日㈭13:30~14:10 第2会場 神経内分泌腫瘍イメージングによるプレシジョンメディシン 座長:佐賀 恒夫(京都大学医学部附属病院放射線診断科) 西井 龍一(量子科学技術研究開発機構 放射線医学総合研究所) 1.ソマトスタチン受容体シンチグラフィー:インジウム111標識オクトレオチド (総合南東北病院放射線科)窪田 和雄 2.68Ga-DOTATOCによる神経内分泌腫瘍の画像診断 (京都大学大学院 医学研究科 放射線医学講座(画像診断学・核医学))中本 裕士 核医学教育講演5 11月3日㈭14:10~14:50 第2会場 福島原発事故後 座長:大野 和子(京都医療科学大学 医療科学部 放射線技術学科) 織内 昇(福島県立医科大学ふくしま国際医療科学センター) 1.東電福島第一原子力発電所廃炉、環境除染の現状 (公益財団法人 原子力安全研究協会)石川 秀高 2.福島原発事故後の小児若年者甲状腺癌について (福島県立医科大学甲状腺内分泌学講座)鈴木 眞一 核医学教育講演6 11月3日㈭14:50~15:50 第2会場 甲状腺アイソトープ内用療法の現状-より良い治療効果を得るためのコツ 座長:加藤 克彦(名古屋大学医学部 放射線医学教室) 中駄 邦博(北光記念病院放射線科) 1.バセドウ病に対する放射性ヨウ素内用療法 (天理よろづ相談所病院 RIセンター)御前 隆 2.甲状腺癌のヨウ素治療:おさえておきたいこと (東京女子医科大学 画像診断学・核医学講座)阿部光一郎 ―S80― 第56回日本核医学会学術総会 3.アブレーション治療 (公立松任石川中央病院 甲状腺診療科)横山 邦彦 核医学教育講演7 11月3日㈭15:50~16:50 第2会場 小動物PETイメージング 座長:籏野健太郎(筑波大学医学医療系) 特別企画プログラム 木村 裕一(近畿大学生物理工学部・システム生命科学科) 1.小動物PET装置の基礎 (理化学研究所 ライフサイエンス技術基盤研究センター)和田 康弘 2.小動物PET装置の性能評価、最適化、画像解析 (長崎大学 原爆後障害医療研究所)西 弘大 3.無麻酔下マウス脳PETイメージング (理研分子プローブ機能評価研究チーム)水間 広 核医学教育講演8 11月3日㈭15:30~16:30 第3会場 心臓半導体SPECT:アンガーカメラの限界を超えて 座長:皿井 正義(藤田保健衛生大学循環器内科) 工藤 崇(長崎大学原爆後障害医療研究所アイソトープ診断治療学研究分野) 1.心筋血流予備能測定をめざしたダイナミック半導体SPECT撮影法 (愛媛大学 医学部 放射線科)宮川 正男 2.D-SPECTによる心筋シンチ (名古屋第二赤十字病院 循環器内科)七里 守 核医学教育講演9 11月3日㈭16:30~17:30 第3会場 PET/MRI 座長:田所 匡典(トラストクリニック) 渡部 浩司( 東北大学サイクロトロン・ラジオアイソトープセンター 放射線管理研究部) 1.PET/MRIの概要と臨床 (福島県立医科大学放射線医学講座)伊藤 浩 2.PET/MRIの特徴と可能性:研究的応用 (福井大学高エネルギー医学研究センター)岡沢 秀彦 3.PET/MRハイブリッドイメージング:MRの活用 (九州大学大学院医学研究院 分子イメージング診断学講座)渡邊 祐司 ―S81― 第56回日本核医学会学術総会 核医学看護フォーラム 11月3日㈭9:00~9:40 第7会場 1.核医学看護の新たなる一歩 座長:千田 道雄(先端医療センター分子イメージング研究グループ) 辰巳早百合(大阪府済生会中津病院PETセンター) 特別企画プログラム 1.核医学診療看護師制度の発足とこれからの核医学看護について (自動車事故対策機構 千葉療護センター)片見 晴子 2.甲状腺がんに対する放射性ヨウ素内用療法の看護 (東京慈恵会医科大学附属病院)西島 奈穂 11月3日㈭9:40~10:30 第7会場 2.一般演題 座長:福内 由美(社会医療法人禎心会 セントラルCIクリニック) 西田 洋(藤田保健衛生大学病院 看護部放射線科外来) 1.放射性ヨード内用療法患者に対するアロマセラピーを用いた治療環境改善の試み (旭川医科大学 放射線医学講座)中山 理寛 2.核医学検査に看護師が関わって (旭川医科大学病院 光学医療診療部・放射線部)武田 都子 3.臨床研究で実施するアミロイドPETの結果開示に関する被験者意識の検討 (国立長寿医療研究センター 治験臨床研究推進部)本田 愛 4.当院の18F-FDG検査における看護師の被ばく対策 (藤田保健衛生大学病院)牧 美香 5.心臓アンモニアPET検査における投与量と検査時間が看護師の被ばくに与える影響 (名古屋放射線診断クリニック)鈴木千江子 11月3日㈭10:30~12:00 第7会場 3.認知症と医療安全~広げよう、核医学の和を。伝えよう、私たちの取り組みを~ 座長:對間 博之(茨城県立医療大学放射線技術科学科) 薬師寺優子(近畿大学医学部附属病院 看護部) 1.認知症を持つ患者さんと核医学診療
Recommended publications
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Radiopharmaceuticals and Contrast Media – Oxford Clinical Policy
    UnitedHealthcare® Oxford Clinical Policy Radiopharmaceuticals and Contrast Media Policy Number: RADIOLOGY 034.19 T0 Effective Date: January 1, 2021 Instructions for Use Table of Contents Page Related Policies Coverage Rationale ....................................................................... 1 • Cardiology Procedures Requiring Prior Definitions .................................................................................... 10 Authorization for eviCore Healthcare Arrangement Prior Authorization Requirements .............................................. 10 • Radiation Therapy Procedures Requiring Prior Applicable Codes ........................................................................ 10 Authorization for eviCore Healthcare Arrangement Description of Services ............................................................... 13 • Radiology Procedures Requiring Prior Authorization References ................................................................................... 13 for eviCore Healthcare Arrangement Policy History/Revision Information ........................................... 14 Instructions for Use ..................................................................... 14 Coverage Rationale eviCore healthcare administers claims on behalf of Oxford Health Plans for the following services that may be billed in conjunction with radiopharmaceuticals and/or contrast media: • Radiology Services: Refer to Radiology Procedures Requiring Prior Authorization for eviCore Healthcare Arrangement for additional information.
    [Show full text]
  • 208054Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 208054Orig1s000 MEDICAL REVIEW(S) Clinical Review Phillip B. Davis, MD Priority Review 505(b)(2) NDA Axumin (18F-Fluciclovine) CLINICAL REVIEW Application Type 505 (b) (1) Application Number(s) 208054 Priority or Standard Priority Review Submit Date(s) 9/28/2015 Received Date(s) 9/28/2015 PDUFA Goal Date 5/27/2016 Division/Office DMIP/ODEIV Reviewer Name(s) Phillip B. Davis, MD Review Completion Date 2/26/2016 Established Name 18F-Fluciclovine (Proposed) Trade Name Axumin Applicant Blue Earth Diagnostics Formulation(s) Solution Dosing Regimen 10mCi via intravenous injection Applicant Proposed PET Imaging men with suspected prostate cancer recurrence. Indication(s)/Population(s) Recommendation on Approval Regulatory Action Recommended Positron emission tomography (PET) imaging of men with Indication(s)/Population(s) suspected prostate cancer recurrence. Axumin PET imaging may (if applicable) identify sites of prostate cancer. CDER Clinical Review Template 2015 Edition 1 Version date: June 25, 2015 for initial rollout (NME/original BLA reviews) Reference ID: 3897370 Clinical Review Phillip B. Davis, MD Priority Review 505(b)(2) NDA Axumin (18F-Fluciclovine) Table of Contents Glossary .................................................................................................................................. 8 1 Executive Summary .........................................................................................................10 1.1. Product Introduction ................................................................................................10
    [Show full text]
  • [18F] FACBC (Fluciclovine) PET-CT of Breast Cancer an Exploratory Study
    Journal of Nuclear Medicine, published on April 7, 2016 as doi:10.2967/jnumed.115.171389 Anti-3-[18F] FACBC (Fluciclovine) PET-CT of Breast Cancer: An Exploratory Study Funmilayo I. Tade1, Michael A. Cohen1, Toncred M. Styblo2, Oluwaseun A. Odewole1, Anna I. Holbrook1, Mary S. Newell1, Bital Savir-Baruch3, Xiaoxian Li4, Mark M. Goodman1, Jonathon A Nye1, David M. Schuster1. Author affiliations: 1. Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA 2. Surgery, Emory University, Atlanta, GA, USA 3. Radiology, Loyola University Medical Center, Maywood, Illinois, USA 4. Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA Corresponding Author: David M. Schuster, MD; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, 1364 Clifton Road, Atlanta, GA 30322. Telephone: 404-712-4859, Fax: 404-712-4860, email: [email protected] First Author: Funmilayo Tade, MD, MPH; Research Fellow, Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University Hospital, 1364 Clifton Road, Atlanta, GA 30322. Telephone: 404-712-1348, Fax: 404-712-4860, email: [email protected] Word Count: 4,946 Grant Sponsor: Glenn Family Breast Center Grant; Winship Cancer Institute, Emory University. FLUCICLOVINE PET-CT IN BREAST CANCER The purpose of this study is to explore the uptake of the synthetic amino acid analog positron emission tomography (PET) radiotracer anti-3-[18F] FACBC (fluciclovine) in breast lesions with correlation to histologic and immunohistochemical characteristics. Methods Twelve women with breast lesions underwent 45 minute dynamic PET-CT of the thorax after intravenous administration of 366.3 ±14.8 (337.44 - 394.05) MBq of fluciclovine.
    [Show full text]
  • ACMUI Chairman, Presiding
    Official Transcript of Proceedings NUCLEAR REGULATORY COMMISSION Title: Meeting of the Advisory Committee on the Medical Uses of Isotopes Docket Number: (n/a) Location: Teleconference Date: Monday, March 30, 2020 Work Order No.: NRC-0868 Pages 1-262 NEAL R. GROSS AND CO., INC. Court Reporters and Transcribers 1323 Rhode Island Avenue, N.W. Washington, D.C. 20005 (202) 234-4433 1 UNITED STATES OF AMERICA NUCLEAR REGULATORY COMMISSION + + + + + ADVISORY COMMITTEE ON THE MEDICAL USES OF ISOTOPES + + + + + TELECONFERENCE + + + + + MONDAY, MARCH 30, 2020 + + + + + The meeting was convened by teleconference, at 9:30 a.m., Dr. Darlene F. Metter, ACMUI Chairman, presiding. MEMBERS PRESENT: DARLENE F. METTER, M.D., Chairman A. ROBERT SCHLEIPMAN, Ph.D., Vice Chairman GARY BLOOM, Member VASKEN DILSIZIAN, M.D., Member RONALD D. ENNIS, M.D., Member RICHARD L. GREEN, Member HOSSEIN JADVAR, Member MELISSA C. MARTIN, Member MICHAEL D. O'HARA, Ph.D., Member ZOUBIR OUHIB, Member NEAL R. GROSS COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. (202) 234-4433 WASHINGTON, D.C. 20005-3701 (202) 234-4433 2 MICHAEL SHEETZ, Member MEGAN L. SHOBER, Member HARVEY B. WOLKOV, M.D., Member DESIGNATED FEDERAL OFFICERS: CHRISTIAN EINBERG, Chief, Medical Safety and Events Assessment Branch (MSEB) LISA DIMMICK, Medical Radiation Safety Team Leader, NMSS/MSST/MSEB KELLEE JAMERSON, ACMUI Coordinator NRC STAFF PRESENT: KEVIN WILLIAMS, Deputy Director, Division of Materials Safety, Security, State, and Tribal Programs (MSST) MARYANN AYOADE, NMSS/MSST/MSEB SAID DAIBES, Ph.D., NMSS/MSST/MSEB DANIEL DIMARCO, NMSS/MSST/MSEB JASON DRAPER, NMSS/MSST/MSEB ROBIN ELLIOTT, NMSS/MSST/MSEB JENNIFER FISHER, NMSS/MSST/MSEB SARA FORSTER, NMSS/MSST/MSEB ROBERT GALLAGHAR, R-I/DNMS/MLAB ANITA GRAY, Ph.D., NMSS/MSST/SMPB VINCENT HOLAHAN, NMSS/MSST NEAL R.
    [Show full text]
  • Download Final Programme As
    LETTER OF INVITATION LETTER OF INVITATION WELCOME WORDS by the EANM Congress Chair EANM’20 EANM’20 On behalf of the European Association of Nuclear Medicine, it is my great honour to invite you to the 33rd Annual EANM WORLD LEADING MEETING LEADING WORLD Congress, which will take place virtually from 22 to 30 MEETING LEADING WORLD October 2020. Nuclear Medicine keeps on growing in many number of newer features are also being planned clinical areas, from diagnostic imaging to and we will have a new format for the plenary therapy: our procedures are increasingly being sessions, new top-rated oral presentation sessions incorporated into clinical practice, in a variety of and a new ‘Top Trials’ session. settings and diseases. This success is mostly related to a peculiar characteristic of our specialty, namely A further characteristic of our Congress is its the functional approach to medicine. PET imaging multidisciplinarity, and this will be emphasised works so well because of the unique functional in 2020, with a number of sessions bringing information provided to clinicians, and this feature together physicians from many specialties as well is the key to the ongoing rapid diffusion of Nuclear as specialists in radiochemistry and pharmacy, Medicine. physicists and other professionals. In addition, a dedicated track for technologists will be provided. In recent years, the status of the EANM Congress as the world-leading meeting in Nuclear Medicine If all of this still isn’t enough to motivate you to has been firmly established. The number of attend the EANM’20 Congress virtually, we are attendees in 2019 exceeded that in any previous working on providing some extra entertainment to year, with more than 6950 participants, but we make your virtual experience even more fun.
    [Show full text]
  • Fluorine-18 Labeled Amino Acids for Tumor PET/CT Imaging
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 36), pp: 60581-60588 Review Fluorine-18 labeled amino acids for tumor PET/CT imaging Yiqiang Qi1,2,*, Xiaohui Liu1,2,*, Jun Li4, Huiqian Yao5 and Shuanghu Yuan2,3 1School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong, China 2Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong Cancer Hospital affiliated to Shandong University, Jinan, Shandong, China 3Shandong Academy of Medical Sciences, Jinan, Shandong, China 4Department of Thoracic Surgery, Shandong Provincial Hospital, Jinan, Shandong, China 5Department of Surgery, Juye Coalfield Central Hospital, Heze, Shandong, China *Authors contributed equally to this work Correspondence to: Shuanghu Yuan, email: [email protected] Keywords: Fluorine-18 labeled amino acids, positron emission tomography/computed tomography (PET/CT), tumor metabolism, molecular imaging Received: May 25, 2017 Accepted: July 25, 2017 Published: August 04, 2017 Copyright: Qi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Tumor glucose metabolism and amino acid metabolism are usually enhanced, 18F-FDG for tumor glucose metabolism PET imaging has been clinically well known, but tumor amino acid metabolism PET imaging is not clinically familiar. Radiolabeled amino acids (AAs) are an important class of PET/CT tracers that target the upregulated amino acid transporters to show elevated amino acid metabolism in tumor cells. Radiolabeled amino acids were observed to have high uptake in tumor cells but low in normal tissues and inflammatory tissues.
    [Show full text]
  • Oncologic Applications of Positron Emission Tomography Scanning
    FEP 6.01.26 Oncologic Applications of Positron Emission Tomography Scanning FEP Medical Policy Manual FEP 6.01.26 Oncologic Applications of Positron Emission Tomography Scanning Related Policies: Effective Policy Date: January 1, 2021 6.01.06 - Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography Original Policy Date: June 2012 6.01.20 - Cardiac Applications of Positron Emission Tomography Scanning 6.01.51 - Interim Positron Emission Tomography Scanning in Oncology to Detect Early Response During Treatment Oncologic Applications of Positron Emission Tomography Scanning Description Positron emission tomography (PET) scans are based on the use of positron-emitting radionuclide tracers coupled to organic molecules, such as glucose, ammonia, or water. The radionuclide tracers simultaneously emit 2 high-energy photons in opposite directions that can be simultaneously detected (referred to as coincidence detection) by a PET scanner, comprising multiple stationary detectors that encircle the area of interest. A variety of tracers are used for positron emission tomography (PET) scanning, including oxygen 15, nitrogen 13, carbon 11 choline, fluorine 18, gallium 68, and fluciclovine 18. Because of their short half-life, some tracers must be made locally using an onsite cyclotron. The radiotracer most commonly used in oncology imaging has been fluorine 18 coupled with fluorodeoxyglucose (FDG), which correlates with glucose metabolism. Fluorodeoxyglucose has been considered useful in cancer imaging because tumor cells show increased metabolism of glucose. The most common malignancies studied have been melanoma, lymphoma, lung, colorectal, and pancreatic cancer. This evidence review focuses on the use of radiotracers detected with dedicated PET scanners. Radiotracers, such as FDG, may be detected using single-photon emission computerized tomography cameras, a technique that may be referred to as FDG-single-photon emission computerized tomography imaging.
    [Show full text]
  • Slides Report on Recent Factors Related to the T&E Report, and Are Not That of the Convened Subcommittee
    Overview: 2019-2020 ACMUI Activities Darlene Metter, M.D. ACMUI Chair/Diagnostic Radiologist November 18, 2020 Today’s Agenda • A. Robert Schleipman, Ph.D. (ACMUI Vice-Chair) – ACMUI’s Comments on the Staff’s Evaluation of Training and Experience for Radiopharmaceuticals Requiring a Written Directive • Ms. Melissa Martin (ACMUI Nuclear Medicine Physicist) – ACMUI’s Comments on Extravasations 2 Today’s Agenda cont’d • Mr. Michael Sheetz (ACMUI Radiation Safety Officer) – ACMUI’s Comments on Patient Intervention and Other Actions Exclusive of Medical Events • Hossein Jadvar, M.D., Ph.D. (ACMUI Nuclear Medicine Physician) – Trending Radiopharmaceuticals 3 Overview of the ACMUI • ACMUI Role • Membership • 2019-2020 Topics • Current Subcommittees • Future 4 Role of the ACMUI • Advise the U.S. Nuclear Regulatory Commission (NRC) staff on policy & technical issues that arise in the regulation of the medical use of radioactive material in diagnosis & therapy. • Comment on changes to NRC regulations & guidance. • Evaluate certain non-routine uses of radioactive material. 5 Role of the ACMUI (cont’d) • Provide technical assistance in licensing, inspection & enforcement cases. • Bring key issues to the attention of the Commission for appropriate action. 6 ACMUI Membership (12 members) • Healthcare Administrator (Dr. Arthur Schleipman) • Nuclear Medicine Physician (Dr. Hossein Jadvar) • 2 Radiation Oncologists (Drs. Ronald Ennis & Harvey Wolkov) • Nuclear Cardiologist (Dr. Vasken Dilsizian) • Diagnostic Radiologist (Dr. Darlene Metter) • Nuclear Pharmacist (Mr. Richard Green) 7 7 ACMUI Membership (12 members) • 2 Medical Physicists Nuclear Medicine (Ms. Melissa Martin) Radiation Therapy (Mr. Zoubir Ouhib) • Radiation Safety Officer (Mr. Michael Sheetz) • Patients’ Rights Advocate (Mr. Gary Bloom*) • FDA Representative (Dr. Michael O’Hara) • Agreement State Representative (Ms.
    [Show full text]
  • U.K.Radiopharmacy Roup
    NEWSLETTER U.K. Radiopharmacy G roup 2016 Q3 QUALITY ASSURANCE OF ASEPTIC PRODUCT DEFECT REPORTING PREPARATION SERVICES (QAAPS) 5TH EDITION Following the April edition of the UKRG Newsletter, Dr Alison Beaney, on behalf of the NHS highlighting the importance of adverse reaction and product defect reporting, we have received a Pharmaceutical Quality Assurance Committee and in conjunction with the Royal Pharmaceutical number of these reports. As previously stated, all Society of Great Britain, has published a new of us can play a key role reporting adverse edition of the Quality Assurance of Aseptic reactions, and product defects, but it is also Preparation Services (5th Edition). As a member of important to see the outcome of these reports. the UKRG Committee and Strategic Group, Dr Therefore, a summary of the reports received to Beaney has an excellent understanding of the date this year, is provided below: function of Radiopharmacies and has adapted current Good Manufacturing Practice Guidance Date Product Product Defect Reported from the MHRA and European Commission, into a set of standards that are applicable to all May 16 Tc99m Low Tc99m yield, normal Radiopharmacies not operating under an MHRA generator volume licence. Licensed units may also benefit from this May 16 Mertiatide Low RCP – improved with publication, which expands on current EU GMP time guidance in a manner that may be more applicable May 16 Mertiatide Low RCP: 10% free Tc99m to aseptic units, including Radiopharmacies, in the May 16 Mertiatide Low RCP: 10% free Tc99m
    [Show full text]
  • IAEA TECDOC SERIES Production and Quality Control of Fluorine-18 Labelled Radiopharmaceuticals
    IAEA-TECDOC-1968 IAEA-TECDOC-1968 IAEA TECDOC SERIES Production and Quality Control of Fluorine-18 Labelled Radiopharmaceuticals IAEA-TECDOC-1968 Production and Quality Control of Fluorine-18 Labelled Radiopharmaceuticals International Atomic Energy Agency Vienna @ PRODUCTION AND QUALITY CONTROL OF FLUORINE-18 LABELLED RADIOPHARMACEUTICALS The following States are Members of the International Atomic Energy Agency: AFGHANISTAN GEORGIA OMAN ALBANIA GERMANY PAKISTAN ALGERIA GHANA PALAU ANGOLA GREECE PANAMA ANTIGUA AND BARBUDA GRENADA PAPUA NEW GUINEA ARGENTINA GUATEMALA PARAGUAY ARMENIA GUYANA PERU AUSTRALIA HAITI PHILIPPINES AUSTRIA HOLY SEE POLAND AZERBAIJAN HONDURAS PORTUGAL BAHAMAS HUNGARY QATAR BAHRAIN ICELAND REPUBLIC OF MOLDOVA BANGLADESH INDIA ROMANIA BARBADOS INDONESIA RUSSIAN FEDERATION BELARUS IRAN, ISLAMIC REPUBLIC OF RWANDA BELGIUM IRAQ SAINT LUCIA BELIZE IRELAND SAINT VINCENT AND BENIN ISRAEL THE GRENADINES BOLIVIA, PLURINATIONAL ITALY SAMOA STATE OF JAMAICA SAN MARINO BOSNIA AND HERZEGOVINA JAPAN SAUDI ARABIA BOTSWANA JORDAN SENEGAL BRAZIL KAZAKHSTAN SERBIA BRUNEI DARUSSALAM KENYA SEYCHELLES BULGARIA KOREA, REPUBLIC OF SIERRA LEONE BURKINA FASO KUWAIT SINGAPORE BURUNDI KYRGYZSTAN SLOVAKIA CAMBODIA LAO PEOPLE’S DEMOCRATIC SLOVENIA CAMEROON REPUBLIC SOUTH AFRICA CANADA LATVIA SPAIN CENTRAL AFRICAN LEBANON SRI LANKA REPUBLIC LESOTHO SUDAN CHAD LIBERIA SWEDEN CHILE LIBYA CHINA LIECHTENSTEIN SWITZERLAND COLOMBIA LITHUANIA SYRIAN ARAB REPUBLIC COMOROS LUXEMBOURG TAJIKISTAN CONGO MADAGASCAR THAILAND COSTA RICA MALAWI TOGO CÔTE D’IVOIRE
    [Show full text]
  • Snomed Ct Dicom Subset of January 2017 Release of Snomed Ct International Edition
    SNOMED CT DICOM SUBSET OF JANUARY 2017 RELEASE OF SNOMED CT INTERNATIONAL EDITION EXHIBIT A: SNOMED CT DICOM SUBSET VERSION 1.
    [Show full text]